ProCE Banner Activity

ASSIST-FL: Rituximab Biosimilar GP2013 vs Rituximab in Treatment-Naive Patients With Advanced Follicular Lymphoma

Slideset Download
Conference Coverage
Rituximab biosimilar GP2013 plus CVP demonstrated equivalent ORR and comparable safety profile vs rituximab plus CVP as initial therapy for advanced follicular lymphoma.

Released: December 12, 2016

Expiration: December 11, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen